Loading…
Loading…
The BlackRock Virginia Municipal Bond Trust (BHV) functions as a closed-end mutual fund, concentrating its investments within the fixed-income sector. Launched by BlackRock, Inc., the fund's investment management is handled by BlackRock Advisors, LLC. It primarily directs its capital towards the U.S. fixed income market, with a special focus on high-quality, investment-grade municipal bonds. These specific bonds offer the advantage of being exempt from both federal income taxes and personal income taxes in Virginia. This U.S.-domiciled trust began its operations on April 25, 2002.
Is BHV's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
CEFs fell this week: 7 of 26 sectors rose on price (average -0.88%) and 12 of 26 on NAV (average -0.30%); munis led while convertibles lagged. DMA announced a buyback and +2.2% distribution raise as it entered its term measurement period; ASGI's rights offering was about 34% subscribed at $19.28. At the fund level, NMS (+5.11%) led on price and KF fell the most (-15.39%); on NAV, BGR (+4.62%) led while KF dropped -16.09%.
One year after Biohaven's first TRAP degrader, BHV-1400, was highlighted in the Kidney Week opening plenary, Biohaven's second TRAP degrader for kidney disease expands its Yale-licensed platform into a growing nephrology franchise BHV-1420 is an investigational TRAP™ extracellular protein degrader. It is designed to bind anti-PLA2R autoantibodies, the main driver of disease in most patients with membranous nephropathy, directing them to the liver for degradation without immunosuppression.
Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including certain next-generation follow-on IgG degraders. Biohaven will receive up to $100 million in near-term payments, including $80 million upfront and eligible to receive another $20 million upon a milestone achievement anticipated within a year, and royalties of approximately twenty percent on net sales by Ono in the licensed territory.
Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), a leading international forum for early-phase oncology drug development. First-in-class FGFR3 ADC: BHV-1530 is a first-in-class potential FGFR3-directed antibody-drug conjugate incorporating Biohaven's proprietary TopoIx payload, that has shown early clinical activity with a differentiated and tolerable safety profile.
BlackRock Virginia Municipal Bond Trust (NYSEAMERICAN:BHV - Get Free Report)'s share price crossed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $12.66 and traded as low as $12.47. BlackRock Virginia Municipal Bond Trust shares last traded at $12.47, with a volume of 975